In conclusion, we reinforce SF3B1 mutations as a key biomarker with a very strong negative impact on TTFT in both M-CLL and U-CLL and also highlight XPO1 as an additional highly relevant gene in both subgroups. The gene discussed is XPO1; the disease is B-cell chronic lymphocytic leukemia.